1991 IPO

Regeneron Pharmaceuticals Stock
Regeneron Pharmaceuticals is focused on the development of pharmaceutical products for the treatment of serious medical conditions.
Sign up today and learn more about Regeneron Pharmaceuticals Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Regeneron Pharmaceuticals Stock
Regeneron Pharmaceuticals is a biopharmaceutical company that discovers, develops, and commercializes pharmaceutical products for the treatment of serious medical conditions. The Company has therapeutic candidates in clinical trials for the potential treatment of cancer, eye diseases, and inflammatory diseases, and has preclinical programs in other diseases and disorders. The company’s product portfolio includes EYLEA, an aflibercept injection; ARCALYST, a rilonacept Injection for subcutaneous use; ZALTRAP for metastatic colorectal cancer; trap fusion proteins; and fully human monoclonal antibodies. On March 26, 2012, it was announced that Sanofi and Regeneron are in development with a new cholesterol drug which will help reduce cholesterol up to 72%. Regeneron Pharmaceuticals was founded in 1988 and is currently headquartered in New York, USA.
Funding History
August 2016 | $8.9M |
---|
Management
Vice President, Head, Regeneron Genetics Center
Aris Baras
Manager, Combination Products Engineering
Michael Selzer
Executive Vice President, Research and Development
Neil Stahl
Senior Vice President, Regulatory Affairs
Ned Braunstein
Senior Vice President, Human Resources
Sally Paull
Senior Staff Engineer, Bioreactor Scale-Up and Development
Ashley Witmer
Senior Director, Business Development
Phil Gutry
Founder, President, and Chief Executive Officer
Leonard S. Schleifer
Associate Director
Amy Johnson
Sr Director
Serge Monpoeho
EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase